Rigel Pharmaceuticals published final Phase 1/2 ARROW study data for its once-daily oral RET inhibitor pralsetinib (GAVRETO) in RET fusion-positive metastatic non-small cell lung cancer. The peer-reviewed publication in the Journal of Clinical Oncology includes an additional 42 months of follow-up, extending earlier results. Across 259 patients with measurable disease, the company reported an overall response rate of 70% (including 7% complete responses). Rigel said the safety profile remained manageable, noting three treatment-related deaths in treatment-naive patients in Asia and no new safety signals, with no reported hypersensitivity reactions after prior immunotherapies. Clinicians highlighted sustained activity and the potential role for pralsetinib in patients with measurable CNS metastases at baseline, supporting the value of early biomarker testing for RET fusions as treatment selection evolves.